Quick Access

SARM1 Knockout HEK293 Cell Line

SARM1 Knockout HEK293 Cell Line

SARM1 Knockout Cell Line (HEK293) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.

Cat. No EDC08107
Species Human
Cell Line HEK293
Gene SARM1
Size 1×10⁶cells

Product Details

Cat.No. EDC08107 Product Name SARM1 Knockout HEK293 Cell Line
Cell Line HEK293 Cellosaurus ID CVCL_0045
Cell Line Synonyms Hek293, HEK-293, HEK/293, (HEK)293, HEK 293, HEK,293, 293, 293 HEK, 293 Ad5, Graham 293, Graham-293, Human Embryonic Kidney 293 Gene
NCBI Gene ID Gene Synonyms HsTIR|MyD88-5|SAMD2|SARM|hSARM1
Summary
Enables NAD+ nucleosidase activity; NAD+ nucleosidase activity, cyclic ADP-ribose generating; and identical protein binding activity. Involved in NAD catabolic process and response to axon injury. Is active in mitochondrion. [provided by Alliance of Genome Resources, Apr 2025]
Associated Diseases Non-tumor
Morphology Adherent Passage Ratio 1/5,2days
Complete Culture Medium DMEM + 10% FBS Freezing Medium 95% Complete culture medium+ 5% DMSO
QC Indels validated by Sanger sequencing; sterility confirmed via microbial testing.
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.

STR Profile

LociSTR Info (Sample Cell)
Sample Cell Line: HEK293
STR Info (Cell bank)
Cell Line: HEK293
Allele1Allele2Allele1Allele2
Amelogenin X X
CSF1P0 12 11 12
D2S1338 19 19
D3S1358 15 17 15 17
D5S818 8 8 9
D7S820 11 12 11 12
D8S1179 12 14 12 14
D13S317 12 14 12 14
D16S539 9 13 9 13
D18S51 17 18 17 18
D19S433 15 18 15 18
D21S11 28 30.2 28 30.2
FGA 23 23
Penta D 9 10 9 10
Penta E 7 15 7 15
TH01 7 9.3 7 9.3
TPOX 11 11
vWA 16 19 16 19
D6S1043 11 11
D12S391 19 21 11 15
D2S441 11 15 11 15
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.

FAQ

The choice depends on whether you are studying SARM1's role as the central executioner of axon degeneration or its enzymatic activity as a NAD⁺ glycohydrolase. The Knockout line is the standard tool for asking whether SARM1 is required for activation-induced NAD⁺ depletion — SARM1 is a dormant NAD⁺ hydrolase that, upon activation by NMN/NAD⁺ ratio increase or injury, catalyzes catastrophic NAD⁺ destruction triggering Wallerian axon degeneration. Overexpression is useful for studying constitutively active SARM1 mutants (E642A) or testing inhibitor specificity. For SARM1 research, the EDITGENE Knockout in HEK293 is the standard mechanistic platform — HEK293 has been extensively used for SARM1 biochemistry, structure-function studies, and inhibitor screening. Rescue with wild-type, catalytically-dead (E642A or constitutively active depending on the mutation), or autoinhibition-released SARM1 enables comprehensive mechanism studies. SARM1 is a major therapeutic target for chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and other axonopathies — multiple SARM1 inhibitors are in clinical development.
Yes. SARM1 rescue experiments are well-established for axon degeneration research: • Construct design: use a codon-modified SARM1 sequence with a small C-terminal tag (FLAG, HA). SARM1 contains an N-terminal mitochondrial targeting sequence/ARM autoinhibitory domain, central SAM dimerization domain, and C-terminal TIR catalytic domain — all essential for regulated activation. • Catalytically-dead rescue: the E642A mutation in the TIR domain abolishes NAD⁺ hydrolase activity and is the standard specificity control. • Constitutively active rescue: ARM domain mutations or deletions release autoinhibition, generating constitutively active SARM1 useful for gain-of-function studies. • Functional readout: rescue should restore activation-induced NAD⁺ depletion measured by NAD⁺/NADH ratio assays following NMN treatment or other activation triggers. HEK293 transduces efficiently with lentivirus and is the standard heterologous expression background for SARM1 biochemistry.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
Contact Us
*
*
*
How did you hear about us: